London’s Spex Capital, a number one early-stage investor tackling international healthcare challenges by HealthTech options, as we speak introduced the primary €30 million dedication to its flagship €100 million Enterprise HealthTech Fund.
The fund will make investments globally in early-stage HealthTech startups, from Seed to Sequence A/B, with investments of as much as €5 million.
Spex has partnered with EIT Digital and Penn Drugs/LGH, a number one mutli-hospital well being system within the US that handles over 7 million sufferers annually.
Claudio D’Angelo, Founder and CEO of Spex Capital, stated: “Healthcare faces immense challenges worldwide with ageing populations creating rising affected person demand and systemic value pressures. Our true energy is not only the quantity of corporations we see, however the unparalleled energy of our distribution community to supply them with important industrial and scientific validation.”
A number of different funds have additionally entered or expanded throughout the European healthtech funding area in 2025, indicating sustained investor urge for food for early-stage digital well being and medical innovation.
London-based Meridian Well being Ventures launched a €44.7 million transatlantic fund to again HealthTech startups scaling between the UK and america. Belgium’s Capricorn Companions introduced a €51 million first shut for its Well being-Tech Fund II, focusing on diagnostics, digital well being, and life-science ventures. In France, M2care secured €26 million to speed up enterprise studio exercise in healthcare innovation.
In opposition to this backdrop, Spex Capital’s €100 million Enterprise HealthTech Fund sits among the many largest of the present European initiatives targeted on early-stage well being know-how, highlighting rising institutional confidence within the sector’s potential.
Its partnerships with EIT Digital, Penn Drugs, and long-standing hyperlinks to the NHS present entry to in depth validation networks, an element usually cited as a bottleneck in scaling well being applied sciences.
In a yr the place European healthtech funding surpassed €4 billion in early 2025, in accordance with EU-Startups’ sector overview, Spex Capital’s entry alerts sustained investor confidence in digital well being and medical innovation.
“The provision is robust, however the validation we ship by our community is the game-changer. Digital HealthTech is vital to addressing these challenges, and with this fund, our new partnerships, and a world-class advisory community, we’re uniquely positioned to assist visionary founders delivering transformative options worldwide,” added D’Angelo.
Based in 2021 by serial entrepreneur Claudio D’Angelo, Spex Capital focuses on commercialising and scaling digital well being and medical know-how options throughout main healthcare supply methods worldwide.
The corporate additionally introduced the appointment of Lord Markham, former UK Well being Minister, as Chair of the Board. He has in depth expertise throughout the general public, non-public and voluntary sectors, notably within the enterprise area the place he co-founded a HealthTech enterprise, Cignpost, which grew from €0 to €350 million turnover in 1 yr.
Lord Markham, Chairman, stated: ”I’m delighted to hitch Spex Capital at such a pivotal second for HealthTech. This scale-up fund will unleash groundbreaking startups. I sit up for working with Claudio and the workforce as we speed up the event and adoption of applied sciences that enhance affected person outcomes and reshape healthcare supply globally. “
EU-Startups beforehand coated the agency in February 2023, when Spex Capital first introduced plans for its €100 million HealthTech fund.
